EUCTR2019-001399-13-FR进行中（未招募）1 期
MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable NRAS Melanoma: A Phase Ib/II Trial of Trametinib plus Hydroxychloroquine in Patients with NRAS Melanoma. CHLORO TRAM MEL - CHLORO TRAM ME
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 29
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Histologically confirmed metastatic or locally advanced unresectable malignant melanoma with an activating NRAS mutation.
- •2.Available archival tissue OR if not the patient is willing to provide a baseline tumor biopsy
- •3.Patient must have progressed during or after a first line treatment by immunotherapy (ipilimumab, pembrolizumab, nivolumab).
- •-Progression will be confirmed by two consecutive CT assessements separated by 4 weeks.
- •-Inclusion is possible if patients progress during an adjuvant treatment by immunotherapy or if they progress less than six months after adjuvant treatment discontinuation.
- •-If patients progress six months after adjuvant treatment discontinuation, they have to be treated by a second line of immunotherapy before they can be included in the trial.
- •4.Patient age =18
- •5.Patient Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.
- •6.Patient able to provide informed consent and sign approved consent forms to participate in the study and provide tumor samples
- •7.Patient willing and able to comply with all study procedures and able to take oral medications.
- •8.Patients must be willing and able to undergo skin or tumor biopsies according to the institute’s own guidelines, the study protocol and requirements for such procedures.
- •9.Patients must have measurable disease as defined by RECIST v1.1 criteria
- •10.Adequate bone marrow, renal and liver function determined biologically:
- •-Hematologic: absolute neutrophil count (ANC) =1.5x10e9/L, platelet count =100 x10e9/L, and hemoglobin =9g/dL
- •-Hepatic: total bilirubin level =1.5 x the upper limit of the normal (ULN) range ((except subjects with Gilbert’s Syndrome who must have normal direct bilirubin) and ASAT and ALAT levels =3 ULN. For patients with metastatic disease to the liver allow levels =5 ULN
- •-Renal: estimated creatinine clearance =50ml/min according to the Cockcroft-Gault formula (or local institutional standard method).
- •-Albumin = 27 g/l
- •11.Adequate cardiac function determined by a pre-treatment EKG and cardiac ultra-sound.
- •- QTc interval = 480 ms
- •- Left ventricular ejection fraction (LVEF) =50%
- •12.Women of childbearing potential must have a negative serum or urine pregnancy test at screening.
- •13.Both male and female patients must agree to the use of 2 methods of contraception, with one method being highly effective and the other being either highly effective or less effective as listed in annexe 1 throughout the study and for at least 4 months after last study treatment administration if the risk of conception exists.
- •14.Women of childbearing potential who are continuously not heterosexually active are exempt from contraceptive requirements. However, women of childbearing who abstain from heterosexual activity on a continuous basis must still undergo pregnancy testing as described in this protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 29
- •F.1.3 Elderly (>=65 years)
排除标准
- •1.Prior to the first dose of study treatment patient who received systemic antineoplastic therapy (including unconjugated therapeutic antibodies and toxin immunoconjugates) or any investigational therapy within 4 weeks (6 weeks for nitrosurea or mitomycin-C, antibodies like ipilimumab, pembrolizumab and nivolumab) or within 7-half lives of the investigational therapy prior to starting study treatment, whichever is longer.
- •2.Patient received radiotherapy within 2 weeks prior to the first dose of study treatment except localized radiation therapy for symptomatic bone metastasis
- •3.Patients with multiple primary malignancies may be enrolled if non-melanoma tumor(s) are determined stable by treating investigator and do not require active treatment.
- •4.Patients with symptomatic brain metastases or cranial epidural disease. Asymptomatic patients with brain metastases can be included.
- •5.Has retinal degenerative disease (hereditary retinal degeneration or age-related macular degeneration), history of uveitis, or history of retinal vein occlusion (RVO) or any eye condition that would be considered a risk factor for RVO (e.g., uncontrolled glaucoma or ocular hypertension).
- •6.Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:
- •-Cardio-vascular disorders: Congestive heart failure NYHA class 3 or 4, unstable angina, serious cardiac arrythmias. Stroke, myocardial infarction or other ischemic event within 3 months before first dose.
- •-History of G6PD deficiency
- •-Patients who have neuromuscular disorders that are associated with elevated CK
- •-Impairment of gastrointestinal function or gastrointestinal disease (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection that under the judgement of the PI may impair absorption of study drugs)
- •-Any other condition that would, in the Investigator’s judgment, contraindicate the patient’s participation in the clinical study due to safety concerns or compliance with clinical study procedures.
- •7.Known positive serology for HIV, active Hepatitis B, and/or active Hepatitis C infection.
- •8.Patients who have undergone major surgery = 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure.
- •9.Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
- •10.Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study
- •11.Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v5.0 Grade=3)
研究者
相似试验
已完成
不适用
MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) MelanomaMetastatic NRAS MelanomaNCT03979651Hospices Civils de Lyon29
已完成
1 期
Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant MelanomaAdvanced BRAF Mutant MelanomaNCT02257424Abramson Cancer Center at Penn Medicine50
终止
2 期
MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT00174369Pfizer34
进行中（未招募）
不适用
Expanded Access Study of MEK162 in Metastatic or Unresectable NRAS Mutation-positive MelanomaMetastatic or Unresectable NRAS Mutation-positive MelanomaMedDRA version: 16.1Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2014-001558-40-HUzsoki Hospital
终止
1 期
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.Colonic NeoplasmsBreast NeoplasmsMelanomaNCT00147550Pfizer79